Unity Biotechnology files for dissolution; terminates SF lease with $3.65M payment

Unity Biotechnology, Inc.

Stockholders approved dissolution on Sept 18, 2025; Certificate of Dissolution filed and effective Sept 26, 2025.
Terminated South SF office/lab lease effective March 31, 2026; paid $3.65M prepaid rent ($2.75M cash + $0.9M letter of credit).
Sublease with Initial Therapeutics terminated; company received $0.2M cash and rights to $0.73M letter of credit.
Landlord gets 25% of any future asset monetization proceeds up to $26.9M aggregate cap, reduced by prepaid rent.
Common stock previously delisted from Nasdaq; company winding down through dissolution and liquidation.

item 1.02item 3.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.